Compare Merck & Co., Inc. (MRK) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Oklo Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Oklo Inc trades at $34.7 (market cap $6.43B). The key difference: Merck & Co., Inc. is far larger — about 54.6× Oklo Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Oklo Inc for 32 Days on average.
| MRK | OKLO | |
|---|---|---|
Market Cap | $351.28B | $6.43B |
Volume | 7,969,665 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $156.43 | $174.14 |
52-Week Low | $82.49 | $34.57 |
Typical Hold Time | 98 Days | 32 Days |
Enterprise Value | $398.04B | $3.97B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
OKLO trades at $34.70, down 5.76% in the last 24 hours, with a bearish technical signal from moving averages. The company reported no revenue in 2025 and a net loss of $105.66 million, with a negative net income margin of -12,625.54%. Recent news highlights competition in the nuclear sector and a $1 billion stock sale, while analyst consensus remains bullish with a $78.63 price target.
Outlook: High growth potential in the nuclear energy market, supported by a strong buy rating from analysts. Risks include significant cash burn, lack of revenue, and execution challenges in commercializing reactor technology. The stock's upside depends on successful project deployment and future revenue generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
